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VEEVious cDNA for different alphaviruses opened an opportunity to explore their
attenuation by extensively modifying the viral genomes, an approach that might minimize or exclude the
reversion to the wild-type, pathogenic phenotype. Moreover, the genomes of such alphaviruses can be
engineered to contain RNA elements that would be functional only in cells of vertebrate, but not insect,
origin. In the present study, we developed a recombinant VEEV that is more attenuated than TC-83 and
capable of replicating only in vertebrate cells. This phenotype was achieved by rendering the translation of
the viral structural proteins, and ultimately viral replication, dependent on the internal ribosome entry site of
encephalomyocarditis virus (EMCV IRES). This recombinant virus was viable, but required additional,
adaptive mutations in nsP2 that strongly increased its replication rates. In spite of efﬁcient replication in
cultured vertebrate cells, the genetically modiﬁed VEEV demonstrated a highly attenuated phenotype in
newborn mice, and yet induced protective immunity against VEEV infection.
Published by Elsevier Inc.IntroductionThe Alphavirus genus in the Togaviridae family contains a number
of important human and animal pathogens. These viruses are widely
distributed on all continents, except for the Antarctic region, and
represent a signiﬁcant public health threat (Grifﬁn, 2001; Strauss and
Strauss, 1994). Under natural conditions, most of the alphaviruses are
transmitted by mosquitoes, in which they cause a persistent, life-long
infection that has little effect on the biological functions of the vector.
In vertebrates infected by mosquitoes during their blood meal,
alphaviruses cause an acute infection, characterized by a high-titer
viremia that is a prerequisite of infection of newmosquitoes and virus
circulation in nature.
Venezuelan equine encephalitis virus (VEEV) is one of the most
pathogenic members of the alphavirus genus. It continuously
circulates in South, Central and North America and causes sporadic
epidemics and epizootics that involve humans, horses and other
domestic animals. During the most recent major outbreak in
Venezuela and Colombia (1995) involving subtype IC VEEV, about
100,000 human cases occurred, with over 300 fatal encephalitis cases
estimated (Rivas et al.,1997). During VEEV epizootics, equinemortality
due to encephalitis can reach 83%, and, while the overall mortality ratenc.is low in humans (b1%), neurological disease, including disorientation,
ataxia, mental depression, and convulsions, can be detected in up to
14% of infected individuals, especially children (Johnson and Martin,
1974). The human disease caused by VEEV is characterized as a febrile
illness with chills, severe headache, myalgia, somnolence and
pharyngitis. Young and old individuals develop a reticuloendothelial
infection with severe lymphoid depletion, followed by encephalitis.
The result of the CNS infection is an acute meningoencephalitis that
leads to the death of neuronal cells (Dal Canto and Rabinowitz, 1981).
The neurologic signs appear within 4–10 days of the onset of illness
and include seizures, paresis, behavioral changes and coma.
In spite of the continuous threat of VEEV epidemics, no safe and
efﬁcient vaccines have been designed for this virus. The attenuated
TC-83 strain of VEEV was developed more than four decades ago by
serial passage of a highly virulent Trinidad donkey (TRD) strain of
VEEV in guinea pig heart cells (Berge et al., 1961). Presently, TC-83 is
still the only available vaccine for laboratory workers and military
personnel. Over 8000 people have been vaccinated (Alevizatos et al.,
1967; Burke et al., 1977; Pittman et al., 1996), and the cumulative data
unambiguously demonstrate that nearly 40% of all vaccinees develop a
disease with some symptoms typical of those in cases of natural VEE,
including fever, systemic illness and other adverse effects (Alevizatos
et al., 1967). This TC-83 strain universally kills newborn, but not adult,
mice after i.c. and s.c. inoculation (Paessler et al., 2003), and thus
provides a good starting point for further attenuation and study of the
effects of the mutations on viral pathogenesis.
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molecule of positive polarity that mimics the structure of cellular
mRNAs. The genome RNA contains both a 5′methylguanylate cap and a
3′ polyadenylate tail (Kinney et al., 1989), features which allow
translation of viral proteins by host cell machinery immediately after
release of the genomeRNAs from thenucleocapsids. The5′ two-thirds of
the genome is translated into nonstructural proteins (nsPs) that
comprise the viral components of the replicative enzyme complex
required for replication of the viral genome and transcription of the
subgenomicRNA. The subgenomicRNAcorresponds to the3′ third of the
genome. It is synthesized from the subgenomic promoter and translated
into the viral structural proteins. The attenuated phenotype of the VEEV
strainTC-83 is the result of twomutations in the strainTRDgenome: one
of them replaced an amino acid at position 120 in E2 glycoprotein, and
the second changed nt 3 in the 5′UTR (Davis et al., 1991; Kinney et al.,
1993; Kinney et al., 1989; White et al., 2001). Thus, because of the very
high mutation rate of the alphaviruses, the reversion of TC-83 to a
pathogenic phenotype remains a great concern in the event that the
appropriate selective conditions, such as virus passage in vivo, would
occur. Moreover, VEEV TC-83 is capable of replicating in mosquito cells,
and infecting mosquitoes following vaccination (Pedersen et al., 1972);
therefore, its transmission by mosquitoes remains possible. Ideally, live
arbovirus vaccine strains should not be transmissible by arthropod
vectors, because circulation among reservoir hosts could lead to
unforeseen changes that might include increased virulence. This is
especially true for attenuated strains, produced from wild-type viruses
that rely on small numbers of attenuatingmutations thatmay be subject
to reversion, or for genetically modiﬁed strains that might evolve in
unanticipated ways, if they undergo vector-borne circulation. The
former risk was underscored by detection of the VEEV TC-83 vaccine
strain in mosquitoes collected in Louisiana during 1971 (Pedersen et al.,
1972), outside the epizootic/epidemic area thatwas restricted toTexas. It
was also unambiguously demonstrated that point mutations in
alphavirus genome can dramatically increase the alphavirus epidemic
potential (Brault et al., 2004; Tsetsarkin et al., 2007).
The development of infectious cDNA for alphaviruses opened an
opportunity to explore their attenuation by extensively modifying the
viral genomes, an approach that might minimize or exclude the
reversion to the wt, pathogenic phenotype. Moreover, the genomes of
such alphaviruses can be engineered to contain RNA elements that
would be functional only in cells of vertebrate, but not insect, origin.
Thus, such extensive mutations could prevent transmission of the
genetically modiﬁed viruses by mosquito vectors.
In the present study, we developed a recombinant, attenuated
VEEV, which can only replicate in cells of vertebrate origin. This
phenotype was achieved by causing the translation of the viral
structural proteins and, ultimately, viral replication to depend on the
internal ribosome entry site of encephalomyocarditis virus (EMCV
IRES). The previously published data strongly indicated that this IRES
is supposed to function very inefﬁciently in driving translation in
insect cells (Finkelstein et al., 1999; Woolaway et al., 2001). The
designed recombinant VEEV was viable, but additional, adaptive
mutations in VEEV nsP2 strongly increased its replication rates. In
spite of efﬁcient replication in cultured vertebrate cells, the genetically
modiﬁed VEEV demonstrated a highly attenuated phenotype in
newborn mice. Thus, the designed strategy of genome modiﬁcation
appears to be applicable to other alphaviruses for development of new
vaccine candidates.
Results
Recombinant VEEV TC-83-based viruses
The rationale of this study was to develop alphaviruses capable of
efﬁcient replication in vertebrate cells, but not those of mosquito
origin. Therefore, replication of such viruses had to depend onproteinsor RNA sequences that function only in vertebrate, but not in insect,
cells. To achieve this, we made the expression of the alphavirus
structural proteins dependent on the EMCV IRES. The designed IRES
did not contain the poly(C) sequence, but retained the ﬁrst 4 codons of
EMCVpolyprotein to achieve themost efﬁcient translation of VEEV TC-
83 structural genes. In later experiments, we conﬁrmed that these
additional amino acids had no negative effect on virus replication, but
had a detectable positive effect on the translation of viral structural
proteins (data not shown). In one of the constructs, VEEV/IRES, the
IRES sequence was cloned into the subgenomic RNA downstream of
the nt 30 of the intact 5′UTR (Fig. 1A). Therefore, such virus was ex-
pected to be capable of subgenomic RNA synthesis. In another
recombinant, VEEV/mutSG/IRES, the subgenomic promoter was inacti-
vated by 13 synonymous point mutations (Figs. 1A and B), which were
expected to prevent reversion to an active SG RNA promoter. To
promote synthesis of the VEEV structural proteins, the IRES sequence
was cloned to replace the 5′UTR in the subgenomic RNA.
The genome RNAs of VEEV/IRES, VEEV/mutSG/IRES and unmodi-
ﬁed VEEV TC-83 were synthesized in vitro and transfected into BHK-
21 cells. In the infectious center assay, the VEEV/IRES RNA demon-
strated the same infectivity as did the RNA of VEEV TC-83, and
developed plaques of a uniform size (Figs. 1A and C). This was a strong
indication that no additional, adaptive mutations were required for
productive replication of the designed virus. VEEV/IRES replicated to
titers exceeding 109 PFU/ml, but these ﬁnal titers and virus replication
rates were signiﬁcantly slower than those of VEEV TC-83 (Fig. 1D).
BHK-21 cells transfected with another recombinant viral genome,
VEEV/mutSG/IRES, which had a mutated subgenomic promoter,
produced infectious virus very inefﬁciently (Fig. 1D). In the infectious
center assay, this construct developed mainly pinpoint plaques, and
their number was difﬁcult to estimate. Surprisingly, this virus
demonstrated further evolution upon serial passage and rapidly
developed variants that produced larger plaques (Fig. 1C and data not
shown). The growth curve presented in Fig. 1D represents the release
of both small and large-plaque-forming viruses.
Thus, the results of these experiments indicated that, at least in the
context of the VEEV/IRES genome, EMCV IRES could produce
structural proteins at levels sufﬁcient for VEEV replication. The
construct with a mutated subgenomic promoter, VEEV/mutSG/IRES,
produced a defective-in-replication virus that could evolve for more
efﬁcient replication.
Analysis of adaptive mutations in VEEV/mutSG/IRES
The evolution of VEEV/mutSG/IRES to a large-plaque phenotype
suggested an accumulation of additional mutations in the viral
genome. The reversion to the wt genome sequence was an impossible
event due to the large number of introduced point mutations, so the
location of adaptive mutations was difﬁcult to predict. To identify the
mutations, we randomly selected 5 plaques of VEEV/mutSG/IRES from
the samples harvested at 24 h post-electroporation, and sequenced
the entire genomes (including the 3′ and 5′UTRs) of two plaque-
puriﬁed variants. The list of the mutations identiﬁed is presented in
Fig. 2A. The majority of themwere synonymous and were not present
in the known cis-acting RNA elements. Thus, their effect on virus
replication was very unlikely. However, the genomes of both plaque
isolates contained the same mutation in the nsP2 protein, Y370→C,
and one of the genomes had the next encoded aa changed as well
(K371→Q).
To test the effect of the mutations on virus replication, we cloned
Y370→C and both Y370→C and K371→Q into the original VEEV/
mutSG/IRES construct (Fig. 2B) and compared the RNA infectivity,
virus replication rates and plaque sizes with those of the original
VEEV/mutSG/IRES and other constructs. The same mutations were
also cloned into the VEEV TC-83 genome to test their effect on the
replication of this parental virus. The IRES-encoding genome RNAs
Fig. 1. Replication of the recombinant, EMCV IRES-encoding, VEEV TC-83-derived viruses in BHK-21 cells. (A) Schematic representation of the designed viral genomes, infectivities of
the in vitro-synthesized RNAs in the infectious center assay, virus titers at 24 h post-transfection of 1 μg of the in vitro-synthesized RNAs into BHK-21 cells, and sizes of the plaques,
formed by indicated viruses in BHK-21 cells at 48 h post-transfection. Arrows indicate functional subgenomic promoters. Filled boxes indicate positions of EMCV IRES. (B) Alignment
of the subgenomic promoter-containing fragment of the VEEV TC-83 genome and the corresponding fragment of the VEEV/mutSG/IRES. The position of the promoter is indicated by
open box. The start of the subgenomic RNA in the VEEV TC-83 genome and the beginning of the EMCV IRES are indicated by arrows. The mutations, introduced into the VEEV/mutSG/
IRES genome are shown in lower case letters. (C) Plaques, formed in BHK-21 cells by viruses, harvested at 24 h post-transfection. (D) Replication of the viruses after transfection of 1 μg
of the in vitro-synthesized RNAs into BHK-21 cells.
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and VEEV/mutSG/IRES/2, demonstrated the same infectivity in the
infectious center assay as did VEEV TC-83 RNA, and rescued viruses
formed uniform plaque, having sizes similar to those of the VEEV TC-
83 (data not shown). They also demonstrated a strong increase in
growth (Fig. 2C), but the effect of the second mutation was barely
detectable. Thus, taken together, the data indicated that the Y370→C
mutation in the nsP2 had a strong positive effect on virus replication,
while the second mutation did not noticeably improve it. When
introduced into the VEEV TC-83 genome, the same mutations did not
have any detectable effect on the rates of virus replication or on ﬁnal
titers (Fig. 2C), which suggests that the replication enhancement was
speciﬁc to the VEEV/mutSG/IRES variant.
The identiﬁed aa changes (Y370→C and K371→Q) could represent
only a fraction of possible mutations leading to the efﬁcient
replication of the VEEV/mutSG/IRES. Therefore, in parallel experi-
ments, we sequenced nt 2161–2959 in the other three plaque-puriﬁed
variants, isolated from the samples, harvested at 24 h post-transfec-
tion of the in vitro-synthesized RNAs, and in 5 plaque-puriﬁed viruses,
isolated from the virus stock after additional 3 passages in Vero cells.
(The latter cells are usually used in vaccine development and
production.) We anticipated that such passaging would lead to the
selection of the most efﬁciently replicating viruses. The list of the
identiﬁed mutations is presented in Fig. 3A. Sequencing was
performed directly from the RT-PCR-derived DNA fragments; there-
fore, the presented mutations represent the consensus sequences in
the plaque-derived virus population.
All of the isolates contained mutations in the sequence, corre-
sponding to the carboxy terminal fragment of the RNA helicase
domain of nsP2, and all of the altered amino acids were locatedbetween aa 348 and 424. Moreover, the most commonmutation, both
in the original virus stock, generated after electroporation, and in the
passaged pool, was Y370→C. This was an indication that it likely has
one of the most prominent effects on replication; therefore, the
above-described variant with this particular mutation, VEEV/mutSG/
IRES/1 (Fig. 2B), was used in the experiments outlined in the following
sections.
Effect of the nsP2 Y370→C mutation on virus replication
Identiﬁcation of the adaptive mutation in the carboxy terminal
fragment of the nsP2-associated RNA helicase was surprising and did
not suggest any obvious explanation for the increase in VEEV/mutSG/
IRES replication. This mutation could possibly have a stimulatory effect
either on RNA replication, or the viral structural proteins translation, or
viral particle formation, or replicative complexes compartmentaliza-
tion, etc. However, themost expected effectwas an increase inviral RNA
synthesis. Therefore, we transfected BHK-21 cells with in vitro-
synthesized genomes of different VEEV variants, metabolically labeled
the newly synthesized viral RNAs with [3H]uridine in the presence of
ActD for 4 h beginning 4.5 h post-electroporation, and then analyzed
the RNA by electrophoresis in agarose gels (Fig. 4A). As expected, VEEV/
IRES was capable of subgenomic RNA synthesis, which indicated to us
that the IRES, introduced at the 3′ end of the subgenomic RNA 5′UTR,
did not interfere with the subgenomic promoter activity. VEEV/mutSG/
IRES and its variants with adaptive mutations in nsP2 produced no
detectable SG RNAs. Thus, 13 mutations introduced into the promoter
sequence of these genomes abolished the transcription of the
subgenomic RNA. Surprisingly, the adaptive mutations in the nsP2 did
not have a noticeable effect on RNA genome replication, and VEEV/
Fig. 3. Mutations identiﬁed in the nsP2 protein of VEEV/mutSG/IRES variants dem-
onstrating a large-plaquephenotype. (A) List of themutations identiﬁed in thegenomesof
the plaque-puriﬁed isolates fromvirus stock, harvested at 24 h post-transfection of the in
vitro-synthesized RNA (Orig.), and in the genomes of isolates from the stock that was
additionally passaged three times in Vero cells (Pass.). (B) Localization of the deﬁned
mutations in the VEEV nsP2. The positions of currently known functional domains in
alphavirus nsP2 (Russo et al., 2006; Strauss and Strauss, 1994) are indicated.
Fig. 2. Mutations found in the plaque-puriﬁed VEEV/mutSG/IRES variants, which
demonstrated more efﬁcient replication in BHK-21 cells, and the effect of the deﬁned
adaptive mutations on VEEV TC-83 and VEEV/mutSG/IRES replication. (A) The list of the
mutations, found in the genomes of plaque isolates, compared to published sequence of
VEEV TC-83 (Kinney et al., 1989). (B) The schematic representation of the VEEV TC-83
and VEEV/mutSG/IRES genomes, having either one or two of the identiﬁed mutations,
and the infectivity of the in vitro-synthesized viral RNAs in the infectious center assay.
Functional subgenomic promoters are indicated by arrows, and EMCV IRES by ﬁlled
boxes. (C) Replication of the designed viruses in BHK-21 cells after transfection of 1 μg of
the in vitro-synthesized viral genomes.
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efﬁciently as did the originally designed VEEV/mutSG/IRES genome.
Moreover, the genome RNA replication of all of the variants was very
similar to that of VEEV TC-83. No effect of thesemutationswas detected
in the context of the original VEEV TC-83 RNA as well (see lanes
corresponding to VEEV/1 and VEEV/2). This ﬁnding strongly suggested
that adaptation did not result in an increase in RNA replication.The synthesis of viral structural proteins was evaluated at 12 h
post-electroporation (Fig. 4B). By that time, VEEV/IRES- and VEEV/
mutSG/IRES-speciﬁc capsid and likely other structural proteins were
synthesized ~2-fold less efﬁciently than in the cells transfected with
VEEV TC-83 RNA. This reasonably small difference does not explain
the more than 4 and 7 orders of magnitude lower infectious titers of
VEEV/IRES and VEEV/mutSG/IRES viruses, respectively (compared to
the titers of VEEV TC-83), detected in samples harvested at 12 h post-
transfection (Fig. 1D). Moreover, in this and other experiments, we did
not detect strong difference between the synthesis of viral proteins in
BHK-21 cells containing the original VEEV/mutSG/IRES genomes
versus VEEV/mutSG/IRES/1 and VEEV/mutSG/IRES/2, which had
adaptive mutations in the nsP2 (Fig. 4B). The labeled proteins in
cells infected with the IRES-encoding viruses were distinguished by
their noticeably slower processing of p62 protein and in the presence
of two additional bands, identiﬁed by mass spectrometry as heat-
shock proteins Hsp90 and Hsp72. The biological signiﬁcance of their
induction is not yet clear, but might result from abnormalities in viral
structural protein(s) folding, leading to stress development in the cells
with viral structural proteins expressed from the IRES. The differences
in accumulation of viral structural proteins were more obvious. By
12 h post-transfection with VEEV/IRES and VEEV/mutSG/IRES RNAs,
cells accumulated 4- and 8-fold less capsid, respectively, than did
those transfected with VEEV TC-83 RNA (Fig. 4C). The adaptive
mutations in nsP2 led to a detectably higher (2–3-fold) accumulation
of viral capsid and envelope proteins in the cells, containing VEEV/
mutSG/IRES/1 and VEEV/mutSG/IRES/2 variants, compared to those
having original VEEV/mutSG/IRES. The difference between synthesis
and accumulation of structural proteinsmight be an indication of their
higher degradation rates. However, it is still difﬁcult to understand
how 2–3-fold higher levels of protein expression at 12 h post-
transfection (Fig. 4C) lead to ~1000-fold higher titers of viruses with
mutated nsP2, compared to the titers of VEEV/mutSG/IRES (Fig. 2C).
164 E. Volkova et al. / Virology 377 (2008) 160–169In additional experiments, we assessed the intracellular distribu-
tion of the viral glycoproteins in cells infected with VEEV TC-83, VEEV/
mutSG/IRES and VEEV/mutSG/IRES/1, and analyzed the presence of
these proteins on the cell surface by staining with VEEV-speciﬁc
antibodies. No noticeable difference in the distribution of the
glycoproteins was identiﬁed. We also tested the possibility that the
adaptive mutations caused the formation of an additional packaging
signal in the viral genome; the mutation-containing fragment
(corresponding to nt 2533–2950 of the VEEV genome) was cloned
into the 3′UTRof the VEEV/mutSG/IRES genome, and the recombinant,
in vitro-synthesized RNAwas tested in the infectious center assay. No
increase was detected in plaque size or virus titers, compared to those
of the original VEEV/mutSG/IRES (data not shown). In another variant,
we cloned a subgenomic promoter and a VEEV capsid-coding
sequence into the 3′UTR of VEEV/mutSG/IRES genome to test whetherthe additional capsid expression from the subgenomic RNA would
increase the efﬁciency of virus replication. This modiﬁcation also did
not have any positive effect on virus titers (data not shown).
Thus, taken together, the above-described complex analysis did not
point to obvious mechanistic explanations for the very inefﬁcient
replication of the original VEEV/mutSG/IRES or for the positive effect of
the detectedmutations in VEEV nsP2 on the virus replication. However,
themain aim of the studywas in the development of the VEEV variants,
whose replication depends on the EMCV IRES function, and both VEEV/
IRES and VEEV/mutSG/IRES/1 appeared to meet this goal.
Replication of the IRES-dependent VEEV variants in the mosquito cells
and mosquitoes
The accumulated data about alphavirus replication unambiguously
demonstrate these viruses' genetic instability and high rate of
evolution, resulting in the deletion of any heterologous genes
(Gorchakov et al., 2007; Thomas et al., 2003), particularly if they
have a negative effect on virus replication. Therefore, one of the
critical questions of the study was whether the designed EMCV IRES
insertions would be stable and render the viruses incapable of
replication in mosquito cells. To test this, we infected C710 mosquito
cells with VEEV/IRES and VEEV/mutSG/IRES viruses harvested at 24 h
post-electroporation of the in vitro-synthesized RNAs into BHK-21
cells. VEEV/mutSG/IRES was used instead of the above-described
VEEV/mutSG/IRES/1, with an adaptive mutation Y370→C in the nsP2,
to test the entire library of the variants, released after the RNA
transfection, for the ability to establish replication in mosquito cells.
Notably, in this library, ~50% of the variants likely contained an
indicated Y370→C mutation (Fig. 3A).
On the ﬁrst passage, at 48 h post-infection of C710 cells, the titer of
VEEV/IRES approached1.5×1010 PFU/ml, and a similar titerwasdetected
in the stock, harvested after the second passage (Figs. 5A and B). The
titers of VEEV/mutSG/IRES, in contrast, were 150 PFU/ml after the ﬁrst
passage, which likely reﬂected residual virus used for infection rather
than nascent virus produced in the mosquito cells, and below the
detection limit after the second passage (Fig. 5B). In additional
experiments, we attempted to passage in C710 cells the plaque-puriﬁed
variants of VEEV/mutSG/IRES that contained adaptive mutations in
nsP2, used for design VEEV/mutSG/IRES/1. No infectious virus was ever
recovered after two blind passages (data not shown). In another set of
experiments, VEEV TC-83, VEEV/IRES, VEEV/mutSG/IRES and VEEV/
mutSG/IRES/1 RNAs were directly electroporated into C710 cells, and
titers of the released viruses were tested at different times post-
transfection. Initially, VEEV/IRES demonstrated a strong delay in
replication, but ultimately replicated as efﬁciently as did VEEV TC-83Fig. 4. Analysis of protein and RNA synthesis in BHK-21 cells transfected with the in
vitro-synthesized recombinant viral RNAs. Cells were electroporated with 4 μg of the
indicated RNAs and seeded into 35-mm dishes as indicated in the Materials and
methods. (A) At 4.5 h post-transfection, medium in the wells was replaced by 1 ml of
αMEM supplemented with 10% FBS, ActD (1 μg/ml) and [3H]uridine (20 μCi/ml). After
4 h of incubation at 37 °C, RNAs were isolated and analyzed by agarose gel
electrophoresis as described in the Materials and methods. The positions of viral
genomic and subgenomic RNAs are indicated by G and SG, respectively. The VEEV/IRES-
speciﬁc subgenomic RNA forms a more diffuse band than do other, subgenomic RNA-
producing, viruses, because, in the gel, it co-migrates with the ribosomal 28S RNA. (B) At
12 h post-transfection, proteins were metabolically labeled with [35S]methionine and
analyzed on a sodium dodecyl sulfate-10% polyacrylamide gel as described in the
Materials and methods. The positions of molecular weight markers (kDa) are indicated
at the left side of the gel. The positions of viral structural proteins: C, E1, E2 and p62 (the
precursor of E2) are shown at the right side of the gel. Asterisks indicate the positions of
cellular proteins (the heat-shock proteins), induced by replication of the IRES-encoding
viruses (see text for details). Noticeable differences in capsid mobility indicate the
presence of additional 4 amino acids, which were cloned into IRES-containing viral
genomes (see Materials and methods for details). (C) The same samples of the proteins
were analyzed by Western blotting. Membranes were developed by VEEV-speciﬁc
mouse antibody and anti-mouse IRDye 800 secondary antibody. The intensity of the
capsid-speciﬁc signals was evaluated on LI-COR imager. The positions of viral structural
proteins: C, E1, E2 and p62 (the precursor of E2) are shown at the right side of the gel.
Fig. 6. Replication of VEEV/mutSG/IRES/1 and VEEV TC-83 in the NIH 3T3 cells. Cells
were infected at an MOI of 10 PFU/cell. Media were replaced at the indicated time
points, and virus titers were measured by plaque assay on BHK-21 cells. The same
samples were used to measure IFN-α/β release in biological assays, as described in the
Materials and methods. Concentrations of released IFN-α/β are presented in interna-
tional units (IU) per ml.
Fig. 7. Survival of mice infected with VEEV TC-83 and VEEV/mutSG/IRES/1 viruses. Six-
day-old NIH Swiss mice were inoculated i.c. with ca. 106 PFU of the indicated viruses.
Animals were monitored for 2 months. No deaths occurred after day 9 post-infection in
these experiments.
Fig. 5. Passaging of the recombinant, EMCV IRES-encoding VEEV variants in C710 cells.
(A) The schematic representation of viral genomes. Arrow indicates the position of
the functional subgenomic promoter. Filled box indicates the position of EMCV IRES.
(B) Titers of the recombinant viruses after passaging in C710 cells. Cells in 35-mm dishes
were infected with 400 μl of virus samples harvested either at 24 h post-transfection of
BHK-21 cells with the in vitro-synthesized RNA (P1) or 48 h post-infection of C710 cells
(P2). Samples were harvested at 48 h post-infection, and titers were determined by
plaque assay on BHK-21 cells. Dashed line indicates the limit of detection. n.d. indicates
that titer was below the detection limit. (C) Replication of the indicated viruses after
transfection of 5 μg of the in vitro-synthesized RNAs into C710 cells. Titers were
determined by plaque assay on BHK-21 cells. (D) The deletions of the IRES-speciﬁc
sequence identiﬁed in the plaque-puriﬁed VEEV/IRES variants, demonstrating efﬁcient
replication in C710 cells. The residual EMCV IRES-speciﬁc sequences are indicated by
lower case letters.
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with VEEV/mutSG/IRES and VEEV/mutSG/IRES/1 RNAs (Fig. 5C).
In a parallel experiment, Aedes aegyptimosquitoes were intrathor-
acically inoculated with ca. 105 PFU of VEEV TC-83 and the VEEV/
mutSG/IRES/1 variant (see Materials andmethods for details). None of
the 17 mosquitoes inoculated with the IRES mutant exhibited
detectable virus replication, whereas 17 of 17 mosquitoes inoculated
with the VEEV TC-83 parent strain demonstrated virus replication
with a mean titer of over 106 PFU/mosquito. Thus, the IRES-encoding
VEEV variant VEEV/mutSG/IRES/1 was incapable of replicating in
mosquito cells both in vitro and in vivo.To explain the high titers of VEEV/IRES (capable of producing the
subgenomic RNA variant) after passaging in mosquito cells, we
randomly selected two individual plaque-puriﬁed variants from the
stock, harvested after passaging in mosquito cells, and sequenced the
IRES-containing fragment of the genome. In both isolates, the IRES
sequence was no longer present in the viral genomes, and only 13 and
15 residual nucleotides of the original IRES were found (Fig. 5C).
Thus, replication of VEEV/IRES variant genome in mosquito cells
led to an accumulation of the IRES-negative variants, and VEEV/
mutSG/IRES (having the inactivated subgenomic promoter) did not
develop mutants capable of replicating efﬁciently in the mosquito-
derived cell line.
VEEV/mutSG/IRES/1 variant demonstrates an attenuated phenotype
This study was aimed at development of VEEV variants incapable
of replicating in cells of mosquito origin (and, correspondingly, in
mosquito vectors), but demonstrating a more attenuated phenotype
Fig. 8. Survival following vaccination and challenge of adult mice. Five-to-6-week-old
female NIH Swiss mice were immunized s.c. with VEEV strain TC-83 or the recombinant
virus at a dose of ca. 106 PFU. Four weeks after immunization, mice were challenged s.c.
with ca. 104 PFU of VEEV strain 3908, and mortality was recorded.
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rates of the VEEV/mutSG/IRES/1 variant raised a concern that this
virus might be incapable of replicating in vertebrate cells with intact
IFN-α/β production and signaling. However, this was not the case. The
results of the experiments, presented in Fig. 6, demonstrate that VEEV/
mutSG/IRES/1 replicated in the NIH 3T3 cells, which have no defects in
IFN-α/β secretion and signaling, to the titers above 109 PFU/ml. Its
replication caused a more efﬁcient IFN-α/β induction (Fig. 6), but
apparently the IFN release did not abrogate the already established
virus replication. As shown in BHK-21 cells (Fig. 2C), replication of
VEEV/mutSG/IRES/1 was less efﬁcient than that of the VEEV TC-83
(Fig. 6), which suggested that the IRES-dependent mutant might be
attenuated in vivo. Indeed, after the i.c. inoculation of 6-day-old mice
with ca. 106 PFU, 86% survived the infection and did not develop signs
of encephalitis; in contrast, 92% of the mice were killed by the same
dose of VEEV strain TC-83 (Fig. 7). Taken together, these data indicate
that genetically modiﬁed, IRES-dependent VEEV was more attenuated
than the parental VEEV TC-83.
Nevertheless, the VEEV/mutSG/IRES/1 variant remained immuno-
genic in both neonatal and adult mice. Of the twelve 6-day-old mice
that survived i.c. inoculationwith VEEV/mutSG/IRES/1, 10 survived s.c.
challenge with 104 PFU of wild-type VEEV strain 3908 administered
5 weeks later (data not shown); in contrast, of the 12 sham (PBS)-
infected mice challenged in the same manner, none survived. The
VEEV/mutSG/IRES/1 was also immunogenic in adult mice; one s.c.
immunization with ca. 106 PFU protected 80% of mice against s.c.
challenge 3 weeks later with 104 PFU (~104 LD50) of VEEV strain 3908
(Fig. 8). Neutralizing antibody titers (PRNT80) were b1:20 in all of
these mice immediately before challenge, which suggested that the
incomplete protection after one vaccination was likely a result of a
lower level of IRES-containing virus replication in vivo. Thus, its high
level of attenuation confers a high degree of safety, but repeated
vaccinations will likely be required.
Discussion
The development of the infectious cDNA clones of Sindbis and
other alphaviruses (Davis et al., 1989; Kuhn et al., 1996; Rice et al.,
1987) opened the opportunity not only for reverse genetics experi-
ments aimed at studying different aspects of virus biology and
pathogenesis, but also for the development of new recombinant
vaccines. Attenuation of the viruses by passaging either in tissue
culture or in chicken embryos (Murphy and Chanock, 2001) generally
results from accumulation of small numbers of point mutations in the
structural and nonstructural genes, and in the cis-acting elements ofviral genomes. For example, the VEEV TC-83 vaccine strain relies on
only 2 point mutations for its attenuation, and the high degree of
reactogenicity probably reﬂects the instability of this attenuation
mechanism. This raises a concern about the possible reversion to the
wt pathogenic phenotype during virus replication in vaccinated
individuals. The number of mutations can be additionally increased
by chemical mutagenesis (Morrill et al., 1991), but this procedure also
does not make the introduced changes irreversible. The genetic
manipulations with infectious cDNA clones of the RNA viruses open
great possibilities for stronger modiﬁcation of viral genomes, and
provide an opportunity to introduce either extensive deletions that
would make it impossible to revert to the wt genome sequence
(Blaney et al., 2006; Blaney et al., 2005; Davis et al., 1995; Hart et al.,
2000), or additional genetic material that might enhance the immu-
nogenicity of the variants.
There is also a concern that genetically altered arbovirusesmight be
introduced into the natural circulation, mediated bymosquito vectors,
and may demonstrate further evolution during long-term replication,
either in mosquitoes or during viremia development in vertebrate
hosts. An example is the use of VEEV TC-83, which is capable of
producing levels of viremia in equids sufﬁcient for infecting mosqui-
toes. The isolation of TC-83 from naturally infected mosquitoes
collected in Louisiana (Pedersen et al., 1972) during the 1971 Texas
epidemic demonstrated the risk of transmission of the attenuated
alphaviruses. Therefore, in designing a new generation of live vaccine
strains, it is prudent to make arboviruses not only highly attenuated,
but also capable of replicating only in cells of vertebrate origin. This can
be achieved by cloning cell-speciﬁc RNA elements into viral genomes.
The use of an EMCV IRES opens such an opportunity. In contrast to the
cricket paralysis virus IRES (Jan and Sarnow, 2002), the EMCV-speciﬁc
element was expected to function very inefﬁciently in arthropod cells
(Finkelstein et al., 1999; Woolaway et al., 2001). Therefore, its
application in expressing viral nonstructural and/or structural proteins
could restrict virus replication in mosquito cells and mosquitoes.
In this study, we cloned EMCV IRES into the VEEV TC-83 genome to
make the translation of viral structural genes IRES-dependent. One of
the genomes contained a functional subgenomic promoter and the IRES
in the 5′UTRof the subgenomic RNA. This viruswas viable, but its ability
to produce the subgenomic RNA promoted further evolution, which
resulted in IRES deletion and reversion, most likely, to a standard, cap-
dependent translation of the structural proteins. The latter deletions
made it capable of replicating in mosquito cells. The second variant
with multiple mutations in the subgenomic promoter was stable in
terms of its inability to revert to a cap-dependent translation. Because
such reversion would require not only the IRES deletion, but also the
restoration of the subgenomic promoter, which we inactivated by
13mutations, direct reversion of thesemutations probably represents a
negligible risk. However, this variant developed an interesting way to
evolve to a more efﬁciently replicating phenotype by accumulating
additional, adaptive mutations in the nsP2 gene. These mutations did
not noticeably change the level of viral RNA replication, synthesis of the
viral structural proteins, or their compartmentalization in the cells. The
detected mutations also did not create an additional signal that could
increase the efﬁciency of the genome packaging. Thus, the mechanism
of their functioning remains to be determined. However, the accumu-
lating published data suggest that the packaging of the genomes of the
RNA viruses is strongly determined by the replicative complexes, and
the genomes need to be presented by the functional nsPs to the
structural proteins for particle formation (Khromykh et al., 2001;
Nugent et al.,1999). Ourworking hypothesis is that the helicase domain
of the nsP2 might be involved in the viral genome presentation for its
packaging into the nucleocapsids, and, thus, the identiﬁed mutations
could have a positive effect on the efﬁciency of this process. However,
this hypothesis certainly needs additional experimental testing.
Our study was not the ﬁrst attempt to transform the subgenomic
RNA-producing positive-strand RNA genome virus into an EMCV IRES-
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virus with IRES-containing genome was also viable (Pugachev et al.,
2000) and, most likely, also further evolved, because a two-orders-of-
magnitude increase in virus titers was detected after 5 passages in
Vero cells (Pugachev et al., 2000). Unfortunately, the genomes of the
variant(s) demonstrating more efﬁcient replication were not
sequenced, but one might speculate that EMCV IRES-containing
rubella, a distant relative of alphaviruses such as Sindbis virus or
VEEV (Strauss and Strauss, 1994), had a similar mechanism of
adaptation to more efﬁcient replication in tissue culture.
The new characteristic features of the designed VEEV/mutSG/IRES/
1 virus, which include a lack of the subgenomic promoter, IRES-
dependent translation of the structural genes, and an inability to
replicate in mosquito cells, raise the interesting question of whether
this virus can be considered an alphavirus. At present, it is probably
best to accept the view that it is, because of the structure of the virion
and synthesis of the nonstructural and structural polyprotein from
different cistrons in the RNA genome. Another issue is that the IRES-
encoding VEEV variants have now to deal with clearing the ribosomes
from viral genomes to synthesize the negative-strand intermediate.
This is an important and intensively studied process in poliovirus
replication (Barton et al., 1999). However, in our experiments, the
IRES-encoding VEEV genomes replicated with an efﬁciency similar to
that of the VEEV TC-83. Thus, the ribosome dislodging from viral RNA
templates may be not critical for VEEV RNA replication. However,
based on the lower replication rates of both VEEV/IRES and VEEV/
mutSG/IRES/1 variants, the ribosome clearing may be important in
packaging the genomes into the viral particles.
It should be noted that the main goal of the study was not in
reaching anunderstandingof the newly implied functions of VEEVnsP2
(which we certainly continue to investigate), but rather to develop
VEEV variants that are incapable of replicating in arthropod vectors and
demonstrate a stable, more attenuated phenotype. Slower growth of
the designed VEEV/mutSG/IRES/1 variant in both IFN-α/β-competent
and IFN signaling-deﬁcient (BHK-21) cells, its ability to induce higher
levels of IFN-α/β in tissue culture, its greatly reduced ability to kill
newbornmice even after i.c. inoculation, and its inability to replicate in
mosquito cells suggest that this variantmightmeet those requirements.
Its immunogenicity will be further investigated in different animal
models. Moreover, we believe that other encephalogenic alphaviruses
can be attenuated by using a similar, EMCV IRES-based strategy, which
can be applied in combinationwith other approaches thatwe and other
research groups have developed within the recent years (Aguilar et al.,
2007; Garmashova et al., 2007a,b 2006; Paessler et al., 2003).
Materials and methods
Cell cultures
The BHK-21 cells were kindly provided by Dr. Paul Olivo (Washing-
ton University, St. Louis, MO), and the Vero cells by Dr. Charles Rice
(Rockefeller University, NewYork, NY). TheNIH3T3 cellswere obtained
from the American Type Tissue Culture Collection (Manassas, VA).
These cell lines were maintained at 37 °C in alpha minimum essential
medium (αMEM) supplementedwith 10% fetal bovine serum (FBS) and
vitamins. Mosquito C710 cells were obtained from Dr. Henry Huang
(Washington University, St. Louis, MO) and propagated in DMEM
supplemented with 10% heat-inactivated FBS and 10% tryptose
phosphate broth (TPB).
Plasmid constructs
Standard recombinant DNA techniques were used for all plasmid
constructions. Maps and sequences are available from the authors
upon request. The original plasmid with VEEV TC-83 genome under
the control of SP6 RNA polymerase promoter, pVEEV TC-83, wasdescribed elsewhere (Petrakova et al., 2005). pVEEV/IRES contained
EMCV IRES with the ﬁrst 4 codons of the EMCV polyprotein. This
sequencewas cloned into the VEEV subgenomic RNA-coding sequence
between the end of the 5′UTR (nt 30) and the initiating AUG (Fig. 1A).
pVEEV/mutSG/IRES encoded the VEEV TC-83 genome, in which the
subgenomic promoter was inactivated by clustered point mutations,
which did not modify the amino acid sequence of the carboxy
terminus of nsP4 (Figs. 1A and B). This viral genome had the 5′UTR of
the subgenomic RNA deleted. Thus, VEEV TC-83 nonstructural and
structural proteins were expected to be synthesized from the same
genomic RNA. The adaptive mutations were introduced into pVEEV/
mutSG/IRES-encoded nsP2 by PCR ampliﬁcation of the fragments of
interest, followed by replacement of the corresponding fragment in
the original genome. The same PCR-based technique was used for
synthesis cloning of different fragments into the SphI site in the 3′UTR
of the VEEV/mutSG/IRES genome. All of the cloned fragments were
sequenced before further virus-rescue experiments.
RNA transcriptions
Plasmids were puriﬁed by centrifugation in CsCl gradients and
linearized by MluI digestion. RNAs were synthesized by SP6 RNA
polymerase (Ambion) in the presence of cap analog (New England
Biolabs). The yield and integrity of transcripts were analyzed by gel
electrophoresis under non-denaturing conditions. RNA concentration
wasmeasuredonaFluorChemimager (Alpha Innotech), and transcription
reactions were used for electroporation without additional puriﬁcation.
RNA transfections
In all of the experiments, the transfections were performed by
electroporation of the in vitro-synthesized RNA using previously
described conditions (Liljeström et al., 1991). To rescue the viruses, 1 μg
of in vitro-synthesized viral genome RNA was electroporated into the
cells (Liljeström et al., 1991), and then they were seeded into 100-mm
dishes and incubated until cytopathic effects were observed. Virus titers
were determined using a standard plaque assay on BHK-21 cells (Lemm
et al., 1990). To assess the RNA infectivity, 10-fold dilutions of
electroporated BHK-21 cells were seeded in 6-well Costar plates
containing subconﬂuent, naive cells. After 1 h incubation at 37 °C in a
5% CO2 incubator, cells were overlaid with 2ml of MEM-containing 0.5%
Ultra-Pure agarose (Invitrogen) supplementedwith3%FBS. Plaqueswere
stained with crystal violet after 2 day incubation at 37 °C, and infectivity
was determined inplaque-formingunits (PFU) per μgof transfectedRNA.
Sequencing of viral genomes
Large plaqueswere randomly selected during titering of viral stocks
(without staining with neutral red). Viruses were extracted from the
agarose plugs into MEM, and aliquots of the latter media were used to
infect BHK-21 cells in 35-mm dishes. After development of profound
CPE, virus stockswere harvested for further characterization, and RNAs
were isolated from the infected cells by Trizol reagent according to the
instructions of the manufacturer (Invitrogen). ~1000 nt-long, over-
lapping fragments were synthesized using standard RT-PCR techni-
ques, puriﬁed by agarose gel electrophoresis and sequenced.
Sequencing of the 5′UTR was performed by using a FirstChoice RLM-
RACE Kit (Ambion) as described elsewhere (Gorchakov et al., 2004).
Viral replication analysis
One-ﬁfth of the electroporated cells were seeded into 35-mm
dishes. At the times indicated in the ﬁgures, media were replaced, and
virus titers were determined by plaque assay on BHK-21 cells (Lemm
et al., 1990). Alternatively, BHK-21, NIH 3T3 or C710 cells were seeded
into 35-mm dishes and infected at the MOIs indicated in the ﬁgures.
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samples were determined by plaque assay on BHK-21 cells.
Analysis of protein synthesis
BHK-21 cells were electroporated with 4 μg of the indicated RNAs,
and one-ﬁfth of the electroporated cells were seeded into six-well
Costar plates. At 12 h post-transfection, proteins were metabolically
labeled by incubating cells for 30 min in 0.8 ml of DMEM medium
lacking methionine, supplemented with 0.1% FBS and 20 μCi/ml of
[35S]methionine. After this incubation, they were scraped into the
media, pelleted by centrifugation and dissolved in 100 μl of standard
protein loading buffer. Equal amounts of proteins were loaded onto
sodium dodecyl sulfate (SDS)-10% polyacrylamide gels. After electro-
phoresis, gels were dried and autoradiographed.
RNA analysis
To analyze the synthesis of virus-speciﬁc RNAs, cells were
electroporated with 4 μg of the in vitro-synthesized viral RNAs, and
one-ﬁfth of the cells were seeded into 35-mm dishes. At 4.5 h post-
transfection, medium in the wells was replaced by 1 ml of αMEM
supplemented with 10% FBS, ActD (1 μg/ml) and [3H]uridine (20 μCi/
ml). After 4 h of incubation at 37 °C, total cellular RNAs were isolated
by Trizol (Invitrogen) according the manufacturer's protocol, then
denatured with glyoxal in dimethyl sulfoxide and analyzed by agarose
gel electrophoresis using the previously described conditions (Bre-
denbeek et al., 1993). Gels were impregnated with 2,5-diphenylox-
azole (PPO), dried and autoradiographed.
IFN-α/β assay
The concentrations of IFNα/β in the media were measured by a
previously described biological assay (Trgovcich et al., 1996). Brieﬂy,
L929 cells were seeded in 100 μl of complete media at a concentration
of 5×104 cells/well in 96-well plates and incubated at 37 °C for 6 h.
Samples of media harvested from infected NIH 3T3 cells were treated
with UV light for 1 h, and serially diluted in two-fold steps directly in
the wells with L929 cells. After incubation for 24 h at 37 °C, an
additional 100 μl of mediawith 2×105 PFU of vesicular stomatitis virus
(VSV) was added to the wells and incubation continued for 36–40 h.
Then cells were stained with crystal violet, and the end point was
determined as the concentration of IFNα/β required for protecting 50%
of the cells from the VSV-induced CPE. The IFN-α/β standard for
normalization of the results was purchased from the ATCC.
Evaluation of virus replication in mosquitoes
To assess replication competence in mosquitoes in vivo, intrathor-
acic inoculations of A. aegypti (a colony originating in Galveston,
Texas) mosquitoes using 105 PFU in a 1 μl volume were used.
Intrathoracic inoculation was selected over oral exposure because
nearly any culicine mosquito is highly susceptible to intrathoracic
infection by any alphavirus, while oral susceptibility is highly variable
and much less sensitive (Weaver, 1997). Following inoculation using a
glass pipette, mosquitoes were incubated for 10 days at 27 °C and then
triturated individually in 1 ml of MEM supplemented with 20% FBS
and Fungizone. A 100 μl volume of each triturated mosquito was then
added to a Vero cell monolayer on a 24-well plate, and cells were
observed for 5 days for cytopathic effects to detect infection. Assay
included the TC-83 parent virus and the IRES mutant.
Immunization and challenge with virulent VEEV
Six-day-old NIH Swiss mice were inoculated intracerebrally (i.c.)
with VEEV TC-83 strain or the designedmutant at a dose of ca. 106 PFUin a total volume of 20 μl of PBS. After infection, each cohort of 8–10
animals was maintained for 2 months without any manipulation. For
21 days, mice were observed daily for signs of illness (rufﬂed fur,
depression, anorexia and/or paralysis) and/or death.
Eight-week-old female NIH Swiss mice were vaccinated s.c. at a
dose of ca. 106 PFU/mouse using VEEV TC-83 or the recombinant virus,
then challenged subcutaneously 4 weeks later with ca. 104 PFU of
highly virulent VEEV strain 3908. For 21 days, mice were observed
twice daily for signs of illness (rufﬂed fur, depression, anorexia and/or
paralysis) and/or death.
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